Home › Compare › HUMDF vs GBDC

HUMDF vs GBDC: Dividend Comparison 2026

HUMDF yields 484.14% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HUMDF wins by $47879.16M in total portfolio value
10 years
HUMDF
HUMDF
● Live price
484.14%
Share price
$0.41
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47900.01M
Annual income
$34,060,653,223.60
Full HUMDF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — HUMDF vs GBDC

📍 HUMDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHUMDFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HUMDF + GBDC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
HUMDF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HUMDF
Annual income on $10K today (after 15% tax)
$41,152.26/yr
After 10yr DRIP, annual income (after tax)
$28,951,555,240.06/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, HUMDF beats the other by $28,937,572,116.30/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HUMDF + GBDC for your $10,000?

HUMDF: 50%GBDC: 50%
100% GBDC50/50100% HUMDF
Portfolio after 10yr
$23960.43M
Annual income
$17,038,551,978.72/yr
Blended yield
71.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

HUMDF
No analyst data
Altman Z
3.9
Piotroski
5/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HUMDF buys
0
GBDC buys
0
No recent congressional trades found for HUMDF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHUMDFGBDC
Forward yield484.14% ✓11.86%
Annual dividend / share$2.00 ✓$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1% ✓
Portfolio after 10y$47900.01M ✓$20.85M
Annual income after 10y$34,060,653,223.60 ✓$16,450,733.83
Total dividends collected$46687.76M ✓$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: HUMDF vs GBDC ($10,000, DRIP)

YearHUMDF PortfolioHUMDF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$59,114$48,414.43$12,492$1,791.70+$46.6K → HUMDF
2$330,728$267,475.81$16,527$3,160.58+$314.2K → HUMDF
3$1,752,431$1,398,551.73$23,588$5,904.90+$1.73M → HUMDF
4$8,800,812$6,925,711.29$37,141$11,901.65+$8.76M → HUMDF
5$41,922,789$32,505,919.38$66,205$26,463.38+$41.86M → HUMDF
6$189,569,894$144,712,509.91$137,452$66,612.65+$189.43M → HUMDF
7$814,403,207$611,563,420.90$342,372$195,298.53+$814.06M → HUMDF
8$3,326,842,984$2,455,431,552.18$1,053,292$686,954.33+$3325.79M → HUMDF
9$12,933,979,587$9,374,257,594.32$4,111,439$2,984,416.95+$12929.87M → HUMDF
10$47,900,011,382$34,060,653,223.60$20,849,974$16,450,733.83+$47879.16M → HUMDF

HUMDF vs GBDC: Complete Analysis 2026

HUMDF — Stock

Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.

Full HUMDF Calculator →

GBDC — BDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this HUMDF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HUMDF vs SCHDHUMDF vs JEPIHUMDF vs OHUMDF vs KOHUMDF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.